BODIPY dyes in photodynamic therapy
Top Cited Papers
- 26 September 2012
- journal article
- review article
- Published by Royal Society of Chemistry (RSC) in Chemical Society Reviews
- Vol. 42 (1), 77-88
- https://doi.org/10.1039/c2cs35216h
Abstract
BODIPY dyes tend to be highly fluorescent, but their emissions can be attenuated by adding substituents with appropriate oxidation potentials. Substituents like these have electrons to feed into photoexcited BODIPYs, quenching their fluorescence, thereby generating relatively long-lived triplet states. Singlet oxygen is formed when these triplet states interact with 3O2. In tissues, this causes cell damage in regions that are illuminated, and this is the basis of photodynamic therapy (PDT). The PDT agents that are currently approved for clinical use do not feature BODIPYs, but there are many reasons to believe that this situation will change. This review summarizes the attributes of BODIPY dyes for PDT, and in some related areas.Keywords
This publication has 77 references indexed in Scilit:
- Thienyl-substituted BODIPYs with strong visible light-absorption and long-lived triplet excited states as organic triplet sensitizers for triplet–triplet annihilation upconversionRSC Advances, 2012
- Designing Excited States: Theory‐Guided Access to Efficient Photosensitizers for Photodynamic ActionAngewandte Chemie-International Edition, 2011
- Optimal Photosensitizers for Photodynamic Therapy of Infections Should Kill Bacteria but Spare NeutrophilsPhotochemistry and Photobiology, 2011
- Photodynamic therapy of cancer: An updateCA: A Cancer Journal for Clinicians, 2011
- Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of CancerMolecules, 2011
- Skin penetration and deposition of carboxyfluorescein and temoporfin from different lipid vesicular systems: In vitro study with finite and infinite dosage applicationInternational Journal of Pharmaceutics, 2011
- Vascular-targeted photodynamic therapy with BF2-chelated Tetraaryl-Azadipyrromethene agents: a multi-modality molecular imaging approach to therapeutic assessmentBritish Journal of Cancer, 2009
- Selective photoinactivation of protein function through environment-sensitive switching of singlet oxygen generation by photosensitizerProceedings of the National Academy of Sciences of the United States of America, 2008
- Comparative characterization of the efficiency and cellular pharmacokinetics of Foscan®- and Foslip®-based photodynamic treatment in human biliary tract cancer cell linesPhotochemical & Photobiological Sciences, 2007
- Clinical Pharmacokinetics of VerteporfinThe Journal of Clinical Pharmacology, 2002